TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids
Brief Summary: The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.


Options:
A: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone propionate
B: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo
C: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
D: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids
Brief Summary: The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.


Options:
A: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tiotropium low dose | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tiotropium high dose | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium high dose; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: tiotropium low dose; Assigned to Arm(s): A
D: Arm Label: CHF 5993 100/6/12.5 µg; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 100/6/12.5 µg | Arm Label: CHF 1535 100/6 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHF 1535 100/6 µg | Intervention Type: DRUG; Name: CHF 5993 100/6/12.5 µg; Assigned to Arm(s): CHF 5993 100/6/12.5 µg | Intervention Type: DRUG; Name: CHF 1535 100/6 µg; Assigned to Arm(s): CHF 1535 100/6 µg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Pre-Pregnancy Supplements
Brief Summary: The purpose of this study is to determine whether daily oral supplements of multivitamins (including vitamins B-complex, C and E) along with Iron and folic acid given to non-pregnant women results in lower prevalence of anemia in preparation for pregnancy when compared to daily iron and folic acid supplements or folic acid alone.


Options:
A: Arm Label: 400 micrograms of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Arm Label: 4mg of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Intervention Type: DRUG; Name: Folic acid: 4 mg versus 0.4 mg per day; Assigned to Arm(s): 400 micrograms of folic acid, 4mg of folic acid
B: Arm Label: Multiple micronutrient - 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and folic acid - 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic Acid - 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multiple Micronutrient - 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and Folic Acid - 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic acid - 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient; Assigned to Arm(s): Multiple Micronutrient - 2, Multiple micronutrient - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and Folic Acid; Assigned to Arm(s): Iron and Folic Acid - 2, Iron and folic acid - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid - 1, Folic acid - 2
C: Arm Label: Folic Acid and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic Acid and Iron | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multivitamins, Folic Acid, and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins, Folic Acid, and Iron; Assigned to Arm(s): Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid and Iron; Assigned to Arm(s): Folic Acid and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid
D: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Pre-Pregnancy Supplements
Brief Summary: The purpose of this study is to determine whether daily oral supplements of multivitamins (including vitamins B-complex, C and E) along with Iron and folic acid given to non-pregnant women results in lower prevalence of anemia in preparation for pregnancy when compared to daily iron and folic acid supplements or folic acid alone.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3
B: Arm Label: Ferrous sulfate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: ferrous sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous sulfate; Assigned to Arm(s): Ferrous sulfate | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Iron supplements; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ferrous gluconate | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous gluconate; Assigned to Arm(s): Iron supplements
D: Arm Label: Folic Acid and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic Acid and Iron | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multivitamins, Folic Acid, and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins, Folic Acid, and Iron; Assigned to Arm(s): Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid and Iron; Assigned to Arm(s): Folic Acid and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Brief Summary: The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.


Options:
A: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
B: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
C: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting
Brief Summary: The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine among males 18-24 years old, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3 at 12 months.

Hypothesis: The Geometric mean titers in the 12 month test group (T) are non-inferior to the usual timing control group (C):

H0: δ ≤ -δ0 versus H1: δ \> -δ0 where δ = log (GMTT )- log (GMTC) and δ0 is the pre-specified non-inferiority margin


Options:
A: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
C: Arm Label: Quadrivalent HPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine for Male Participants Only, Biological: Placebo Vaccine for Female Participants Only | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV Vaccine; Assigned to Arm(s): Quadrivalent HPV Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Male Participants Only; Assigned to Arm(s): Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Female Participants Only; Assigned to Arm(s): Placebo Vaccine
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections in Long-Acting Reversible Contraceptive Users
Brief Summary: This study randomizes women using long-acting reversible methods of contraception to home-based STD screening through the mail compared to screening available in a clinical setting. We hypothesize that women randomized to home-based screening will be more likely to complete screening.


Options:
A: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
B: Arm Label: Home; Type: EXPERIMENTAL; Interventions: Behavioral: Home screening | Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic screening | Intervention Type: BEHAVIORAL; Name: Home screening; Assigned to Arm(s): Home | Intervention Type: BEHAVIORAL; Name: Clinic screening; Assigned to Arm(s): Clinic
C: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
D: Arm Label: Deferred screening control group; Type: OTHER; Interventions: Procedure: Screening for chlamydia using self-taken vaginal swabs | Intervention Type: PROCEDURE; Name: Screening for chlamydia using self-taken vaginal swabs; Assigned to Arm(s): Deferred screening control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections in Long-Acting Reversible Contraceptive Users
Brief Summary: This study randomizes women using long-acting reversible methods of contraception to home-based STD screening through the mail compared to screening available in a clinical setting. We hypothesize that women randomized to home-based screening will be more likely to complete screening.


Options:
A: Arm Label: Home; Type: EXPERIMENTAL; Interventions: Behavioral: Home screening | Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic screening | Intervention Type: BEHAVIORAL; Name: Home screening; Assigned to Arm(s): Home | Intervention Type: BEHAVIORAL; Name: Clinic screening; Assigned to Arm(s): Clinic
B: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Self-collected vaginal swab for chlamydia testing; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy of Erythropoietin Produced in the Institute of Technology in Immunobiology of the Oswald Cruz Foundation (BioMaguinhos/FioCruz/MS) and Erythropoietin Industrialized in Patients With Chronic Renal Failure
Brief Summary: A double-blind, randomized trial aimed to compare the efficacy of two formulations of erythropoietin in patients with chronic renal failure on hemodialysis


Options:
A: Arm Label: Epoetin Bio-Manguinhos; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa-BioManguinhos | Arm Label: EPO-BioSimilar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa-BioSimilar | Intervention Type: DRUG; Name: Epoetin Alfa-BioManguinhos; Assigned to Arm(s): Epoetin Bio-Manguinhos | Intervention Type: DRUG; Name: Epoetin Alfa-BioSimilar; Assigned to Arm(s): EPO-BioSimilar
B: Arm Label: Erythropoiesis Stimulating Agents; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: Epoetin Beta, Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Methoxy Polyethylene Glycol-Epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta
C: Arm Label: Correction Phase: CERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Arm Label: Correction Phase: Epoetin Beta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]; Assigned to Arm(s): Correction Phase: CERA | Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): Correction Phase: Epoetin Beta
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation
Brief Summary: The objectives of this study are to test if hypoxia in muscle tissue is an important factor contributing to clinical symptoms in chronic rheumatic muscle inflammation and to evaluate if a 12 week endurance exercise program will improve muscle tissue hypoxia and disability in patients with chronic rheumatic muscle inflammation.


Options:
A: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise on a cycle-ergometer | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise on a cycle-ergometer; Assigned to Arm(s): Exercise
C: Arm Label: Sjogren and Myositis Control (no control for takayasu's); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sjogren, Myositis and Takayasu's Trained; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Sjogren, Myositis and Takayasu's Trained
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Physical Exercise | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical Exercise; Assigned to Arm(s): Exercise

Answer: D